Pombiliti, used with Opfolda (miglustat), treats adults with late-onset Pompe disease who aren’t responding to enzyme replacement therapy. It delivers an enzyme to break down muscle-accumulated glycogen, improving muscle strength and lung function.
Pombiliti, used with Opfolda (miglustat), treats adults with late-onset Pompe disease who aren’t responding to enzyme replacement therapy. It delivers an enzyme to break down muscle-accumulated glycogen, improving muscle strength and lung function.
Molecule Name :
Innovator :
Approval Date :
Data Exclusivity Expiry :
Market Exclusivity Expiry :
Dosage Form :
Strength :
Therapeutic Category :
Revenue ($M) :
2025 :
2026 :
2027 :
2028 :
2029 :
2030 :
2031 :




